Colorectal Cancer Epidemiology and Treatment

Colorectal cancer is a malignant neoplasm of the colon or rectum and one of the most common cancers worldwide. Most cases arise through a stepwise progression from adenomatous polyps, which makes the disease amenable to screening and early detection. Its epidemiology, molecular pathways, staging, and stage- and biomarker-directed treatment are the core of colorectal oncology.

Definition

Colorectal cancer is a malignant tumor arising from the epithelium of the colon or rectum, most often as an adenocarcinoma developing through the adenoma-carcinoma sequence, and staged by depth of invasion, nodal involvement, and metastasis.

Scope

This topic covers the descriptive epidemiology of colorectal cancer, the adenoma-carcinoma sequence and key molecular pathways, the rationale for screening, and the principles of treatment by stage and molecular markers (including RAS status and mismatch-repair status). It is a reference overview of the disease and its evidence base, not individualized clinical advice.

Core questions

• How does the adenoma-carcinoma sequence make colorectal cancer screenable?
• Which molecular pathways and biomarkers (e.g., RAS, mismatch-repair status) shape treatment?
• How does stage determine the role of surgery, adjuvant chemotherapy, and systemic therapy?
• What is the evidence basis for population colorectal cancer screening?

Key concepts

• Adenoma-carcinoma sequence
• Chromosomal instability and microsatellite instability pathways
• RAS mutation status and anti-EGFR therapy
• Mismatch-repair deficiency and immunotherapy
• Colorectal cancer screening (e.g., colonoscopy, stool-based tests)
• TNM staging and adjuvant therapy in stage III disease

Mechanisms

Most colorectal cancers develop slowly from benign adenomatous polyps through an accumulation of genetic and epigenetic changes (the adenoma-carcinoma sequence), commonly via a chromosomal-instability pathway and, in a subset, via microsatellite-instability driven by mismatch-repair deficiency (Brenner et al., 2014). These molecular features carry treatment implications: tumors with RAS mutations do not benefit from anti-EGFR antibodies, so RAS status predicts response (Karapetis et al., 2008), while mismatch-repair-deficient tumors are responsive to immune checkpoint blockade (Le et al., 2015). This stepwise biology also underlies the effectiveness of screening, because precursor lesions can be detected and removed.

Clinical relevance

Colorectal cancer is a model of a screenable cancer with a well-characterized precursor lesion and of biomarker-directed systemic therapy. This entry describes that biology, epidemiology, and evidence structure; it does not provide individualized diagnostic or treatment recommendations.

Epidemiology

Colorectal cancer is among the most commonly diagnosed cancers and a major cause of cancer death worldwide, with incidence varying by region and influenced by diet, obesity, physical inactivity, smoking, and inherited syndromes (Bray-era global statistics; Brenner et al., 2014). In several high-income countries overall incidence has declined with screening, even as early-onset disease in younger adults has risen, a trend documented in recent statistical reports (Siegel et al., 2020).

Evidence & guidelines

Randomized and observational evidence supports colorectal cancer screening to reduce incidence and mortality through detection and removal of precursor polyps and early cancers. In systemic therapy, randomized trials established RAS testing to select patients for anti-EGFR antibodies (Karapetis et al., 2008), refined the duration of adjuvant chemotherapy in stage III disease (Grothey et al., 2018), and demonstrated immunotherapy activity in mismatch-repair-deficient tumors (Le et al., 2015). Guidelines integrate stage and molecular markers; specifics evolve and should be read in current sources.

History

The recognition that most colorectal cancers arise from adenomatous polyps established the adenoma-carcinoma sequence and the rationale for screening, and the molecular dissection of the pathway became a textbook model of stepwise carcinogenesis. Treatment advanced from surgery and fluoropyrimidine chemotherapy to biomarker-directed therapy in the 2000s, with RAS-guided anti-EGFR therapy and, later, immunotherapy for mismatch-repair-deficient disease.

Debates

Rising incidence of early-onset colorectal cancer

Colorectal cancer is increasingly diagnosed in adults younger than traditional screening ages in several countries, prompting debate over screening start ages and the still-uncertain drivers of this trend.

Seminal works

• karapetis-2008
• le-2015
• grothey-2018
• brenner-2014

Frequently asked questions

Why can colorectal cancer be screened for effectively?

Most colorectal cancers develop slowly from benign adenomatous polyps, so screening can detect and remove precursor lesions before they become cancer or find cancers at an early, more treatable stage.

Why is RAS (KRAS) testing done in colorectal cancer?

Tumors carrying RAS mutations do not benefit from anti-EGFR antibody therapy, so RAS status is tested to predict whether that class of treatment is likely to work, illustrating biomarker-directed therapy.